(Q38307722)

2 September 2017

title

Rev-binding aptamer and CMV promoter act as decoys to inhibit HIV replication (English)

1 reference

2 September 2017

Konopka K

1

1 reference

2 September 2017

Lee NS

series ordinal

2

1 reference

2 September 2017

Rossi J

series ordinal

3

1 reference

2 September 2017

Düzgüneş N

series ordinal

4

1 reference

2 September 2017

language of work or name

English

0 references

publication date

1 September 2000

1 reference

2 September 2017

1 reference

2 September 2017

volume

255

1 reference

2 September 2017

issue

2

1 reference

2 September 2017

page(s)

235-244

1 reference

Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0378-1119%2800%2900334-6

7 January 2021

Cell-type-specific modulation of PDGF-B regulatory elements via viral enhancer competition: a caveat for the use of reference plasmids in transient transfection assays

1 reference

https://api.crossref.org/works/10.1016%2FS0378-1119%2800%2900334-6

7 January 2021

A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-1119%2800%2900334-6

7 January 2021

A molecular clone of HTLV-III with biological activity.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-1119%2800%2900334-6

7 January 2021

Cellular transcription factors involved in the regulation of HIV-1 gene expression

1 reference

https://api.crossref.org/works/10.1016%2FS0378-1119%2800%2900334-6

7 January 2021

Expression of small, therapeutic RNAs in human cell nuclei.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-1119%2800%2900334-6

7 January 2021

Inhibition of human immunodeficiency virus replication by the herpes simplex virus virion host shutoff protein

1 reference

https://api.crossref.org/works/10.1016%2FS0378-1119%2800%2900334-6

7 January 2021

Control of RNA initiation and elongation at the HIV-1 promoter

1 reference

https://api.crossref.org/works/10.1016%2FS0378-1119%2800%2900334-6

7 January 2021

Structural arrangements of transcription control domains within the 5'-untranslated leader regions of the HIV-1 and HIV-2 promoters

1 reference

https://api.crossref.org/works/10.1016%2FS0378-1119%2800%2900334-6

7 January 2021

Gene therapy for HIV-1 infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-1119%2800%2900334-6

7 January 2021

Human immunodeficiency virus type-1 (HIV-1) infection increases the sensitivity of macrophages and THP-1 cells to cytotoxicity by cationic liposomes

1 reference

https://api.crossref.org/works/10.1016%2FS0378-1119%2800%2900334-6

7 January 2021

Receptor ligand-facilitated cationic liposome delivery of anti-HIV-1 Rev-binding aptamer and ribozyme DNAs.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-1119%2800%2900334-6

7 January 2021

Inhibition of human immunodeficiency virus type 1 in human T cells by a potent Rev response element decoy consisting of the 13-nucleotide minimal Rev-binding domain.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-1119%2800%2900334-6

7 January 2021

The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain

1 reference

https://api.crossref.org/works/10.1016%2FS0378-1119%2800%2900334-6

7 January 2021

Development of a self-inactivating lentivirus vector.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-1119%2800%2900334-6

7 January 2021

Ribozymes and the anti-gene therapy: how a catalytic RNA can be used to inhibit gene function.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-1119%2800%2900334-6

7 January 2021

A compilation of cellular transcription factor interactions with the HIV-1 LTR promoter

1 reference

https://api.crossref.org/works/10.1016%2FS0378-1119%2800%2900334-6

7 January 2021

Catalytic antisense RNA (ribozymes): their potential and use as anti-HIV-1 therapeutic agents.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-1119%2800%2900334-6

7 January 2021

A high-level expression vector for human cells

1 reference

https://api.crossref.org/works/10.1016%2FS0378-1119%2800%2900334-6

7 January 2021

Non-viral gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0378-1119%2800%2900334-6

7 January 2021

In vitro evolution of functional nucleic acids: high-affinity RNA ligands of HIV-1 proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0378-1119%2800%2900334-6

7 January 2021

A chimeric human immunodeficiency virus type 1 (HIV-1) minimal Rev response element-ribozyme molecule exhibits dual antiviral function and inhibits cell-cell transmission of HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FS0378-1119%2800%2900334-6

7 January 2021

Inhibition of transcription by the TAR RNA of HIV-1 in a nuclear extract of HeLa cells

1 reference

https://api.crossref.org/works/10.1016%2FS0378-1119%2800%2900334-6

7 January 2021

10.1016/S0378-1119(00)00334-6

Identifiers

DOI

1 reference

2 September 2017

1 reference